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REVIEW
Treating Hepatic Steatosis and Fibrosis by Modulating
Mitochondrial Pyruvate Metabolism
Kyle S. McCommis and Brian N. Finck
Center for Human Nutrition, Department of Medicine, Washington University School of Medicine, St. Louis, Missouri
SUMMARY
This article reviews the recent studies suggesting a potential
role for inhibiting mitochondrial pyruvate metabolism as a
strategy for treatment of nonalcoholic steatohepatitis.
A hepatic comorbidity of metabolic syndrome, known as
nonalcoholic fatty liver disease (NAFLD), is increasing in
prevalence in conjunction with the pandemics of obesity
and diabetes. The spectrum of NAFLD ranges from simple
hepatic fat accumulation to a more severe disease termed
nonalcoholic steatohepatitis (NASH), involving inﬂamma-
tion, hepatocyte death, and ﬁbrosis. Importantly, NASH is
linked to a much higher risk of cirrhosis, liver failure, and
hepatocellular carcinoma, as well as an increased risk
for nonhepatic malignancies and cardiovascular disease.
Interest in the understanding of the disease processes and
search for treatments for the spectrum of NAFLD-NASH has
increased exponentially, but there are no approved phar-
macologic therapies. In this review, we discuss the existing
literature supporting insulin-sensitizing thiazolidinedione
compounds as potential drug candidates for the treatment
of NASH. In addition, we put these results into new context
by summarizing recent studies suggesting these com-
pounds alter mitochondrial metabolism by binding and
inhibiting the mitochondrial pyruvate carrier. (Cell Mol
Gastroenterol Hepatol 2019;7:275–284; https://doi.org/
10.1016/j.jcmgh.2018.09.017)
Keywords: Nonalcoholic Steatohepatitis; Mitochondria;
Pyruvate; Thiazolidinedione.
Interest in better understanding nonalcoholic fattyliver disease (NAFLD) has increased exponentially as
a result of the increasing prevalence of the disease and it
now is appreciated how signiﬁcantly the disease impacts
overall health. NAFLD is a spectrum of disease that ranges
from simple hepatic steatosis to the more severe nonalco-
holic steatohepatitis (NASH), involving hepatocellular
injury, inﬂammation, and hepatic ﬁbrosis. Although
most individuals with steatosis do not progress to NASH,
because of its prevalence, the number of patients that will
develop severe forms of the disease is staggering. In the
United States, it is estimated that more than 83.1 million
people have NAFLD and as many as 27% of these in-
dividuals may have NASH.1 Importantly, NASH increases the
risk of developing cirrhosis, liver failure, and hepatocellular
carcinoma, as well as an increased predisposition to non–
liver-associated diseases such as cardiovascular disease and
cancer.2–6 Despite this high prevalence and the negative
health impact of NASH, there are no approved therapeutic
agents for treating this spectrum of conditions.
Nutrient oversupply is likely a driving force in devel-
oping NAFLD. High levels of dietary fat or sugar, free fatty
acids from adipose tissue, and de novo lipogenesis all likely
contribute to the overabundance of lipids.7 At some point,
and because of factors that are still emerging, lipid accu-
mulation activates inﬂammatory cascades and tissue injury
responses that lead to the development of NASH. Multiple
cell types in the liver play a role in this progression. The
parenchymal cells of the liver, hepatocytes, are the main site
of neutral lipid storage and secrete a number of factors that
can communicate with other cell types to drive the pro-
gression to NASH. Cells of the immune system also play a
role through release of inﬂammatory cytokines and other
factors. Finally, hepatic stellate cells (HSCs) are ﬁbroblastic
cells that migrate to the site of injury and secrete extracel-
lular matrix components that make up the ﬁbrotic lesions
observed histologically in NASH.8 To be considered suc-
cessful, phase 3 clinical trials for NASH will need to show
signiﬁcant histologic improvements in ﬁbrosis or NAFLD
activity scoring (NAS) (assessment of steatosis, hepatocyte
death [ballooning], and inﬂammation) without worsening
other histologic end points.
Obesity-related insulin resistance and type 2 diabetes
are tightly linked to the development of NAFLD and pro-
gression to NASH.9–13 Accumulation of fat has been linked to
impaired insulin signaling via accumulation of speciﬁc spe-
cies of lipids that activate signaling cascades14,15 (Figure 1).
The cause and effect relationship between hepatic steatosis
and insulin resistance is not always clear,16 but abundant
evidence suggests that insulin resistance may drive
local and systemic alterations in metabolism that promote
Abbreviations used in this paper: HSC, hepatic stellate cell; HTF-C,
high trans-fat, fructose, cholesterol diet; MPC, mitochondrial pyruvate
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liver lipid accumulation (Figure 1). For instance, hyper-
insulinemia in insulin-resistant states stimulates hepatic
de novo lipogenesis,17 and this newly synthesized lipid
comprises roughly 25% of the hepatic triglyceride accu-
mulating in NAFLD.18 Insulin-resistant adipose tissue is
linked to higher rates of basal lipolysis and thus exposure of
the liver to increased plasma free fatty acid concentra-
tions.19,20 Indeed, roughly 60% of hepatic triglycerides in
human NAFLD subjects are derived from plasma fatty
acids.18 For some time now, it has been hypothesized that
interventions to treat insulin resistance will have utility for
concomitant attenuation of NAFLD and NASH.
Thiazolidinediones for Treatment of
NASH
Given the tight linkage to insulin resistance, the insulin-
sensitizing thiazolidinediones (TZDs) rosiglitazone and
pioglitazone have been evaluated extensively as NAFLD
treatments.21–28 These antidiabetic and anti-inﬂammatory
compounds are agonists of the nuclear transcription factor
peroxisome proliferator-activated receptor g (PPARg),29
which activates a transcriptional program driving fatty
acid storage and adipocyte differentiation. Unfortunately,
PPARg activation is associated with a number of side effects
such as weight gain, edema, and bone mineral density loss.30
Rosiglitazone, the most potent PPARg agonist, was linked to
increased cardiovascular mortality,31–33 which later was
discounted, but caused clinical use of TZDs to plummet.34 In
addition to their strong insulin-sensitizing effects in high-fat
diet–fed rodents, TZDs markedly reduced inﬂammation35,36
and prevented37 or reversed38 hepatic ﬁbrosis, including
direct effects on stellate cell activation. Unfortunately,
although early studies conducted in human beings produced
results that generally were positive for improving steatosis
and plasma markers for liver injury such as alanine
aminotransferase, they largely did not result in signiﬁcant
histologic improvement with TZD therapy.21–28,39 In the
majority of the early clinical NASH trials with TZD com-
pounds, drug exposures were quite low and for a limited
duration, likely in attempt to avoid these clinical side effects.
Interestingly, a more recent trial using 45 mg/day
pioglitazone for 18–36 months resulted in NASH histologic
improvement, including ﬁbrosis score improvement,
compared with placebo, without signiﬁcant safety issues.40
Although the response to pioglitazone was quite variable in
these subjects, it was shown that the degree of histologic
improvements was correlated with blood pioglitazone
(as well as active drug metabolite hydroxypioglitazone
and ketopioglitazone) concentrations.41 The likelihood of
improvement also was linked to genetic variation in the
CYP2C8 gene,42 which encodes the cytochrome P450
enzyme isoform that metabolizes pioglitazone.43 In addi-
tion, a recent meta-analysis of 8 randomized clinical trials
evaluating pioglitazone or rosiglitazone in NASH concluded
that NASH resolution and ﬁbrosis improvement is
observed with pioglitazone, but not rosiglitazone.44,45
Because pioglitazone shows signiﬁcantly weaker afﬁnity
for PPARg compared with rosiglitazone,29 one must
consider whether additional molecular targets of TZDs are
responsible for the improvements of NASH observed with
pioglitazone.
Figure 1. Insulin resistance drives hepatic steatosis in NAFLD. In the United States and Europe, the majority of NAFLD is
associated with obesity and insulin resistance. For adipose tissue, the inability to respond to insulin results in dysregulated
lipolysis and increased free fatty acids, which then are sequestered by the liver. Hyperinsulinemia and hyperglycemia also
stimulate de novo lipogenesis, which is the creation of new lipids from carbohydrate or amino acid carbon backbones.
Together with enhanced uptake of fats from dietary sources, the liver stores these fatty acids in lipid droplets and becomes
steatotic. Although controversial, hepatic steatosis likely further exacerbates insulin resistance.
276 McCommis and Finck Cellular and Molecular Gastroenterology and Hepatology Vol. 7, No. 2
Downloaded for Anonymous User (n/a) at Washington University School of Medicine from ClinicalKey.com by Elsevier on April 04, 2019.
For personal use only. No other uses without permission. Copyright ©2019. Elsevier Inc. All rights reserved.
Interestingly, a number of PPARg-sparing TZD com-
pounds, including Metabolic Solutions Development
Company (MSDC)-0160 and MSDC-0602, recently were
synthesized and shown to have potent insulin-sensitizing
and antiﬁbrotic effects.46–48 These compounds show
PPARg-binding afﬁnities that are roughly an order of
magnitude less than pioglitazone, and 2 orders of magnitude
less than rosiglitazone.46 MSDC-0160 and MSDC-0602 also
show extremely low PPARg luciferase reporter activa-
tion,46,49 and treatment with MSDC compounds does not
induce PPARg-target genes in cultured adipocytes46 or
cause weight gain in a clinical trial.47 However, the studies
conducted in mice show strong anti-inﬂammatory effects
and evidence of adipose tissue browning.46 These PPARg-
sparing TZD compounds also improve insulin sensitivity in
both mouse models46 and in clinical trials.47 In addition, the
potassium salt of MSDC-0602, MSDC-0602K, reduced liver
injury in a mouse model of NASH by reducing the NAS and
ﬁbrosis scores, as well as acting directly on isolated stellate
cells to suppress their activation. MSDC-0602K is currently
in a phase 2b randomized, double-blinded, clinical trial for
NASH (Effects of Modulation of the Mitochondrial pyruvate
carrier In NASH - Evaluation of a New Chemical Entity
[EMMINENCE]; NCT02784444). These ﬁndings are consis-
tent with alternative molecular targets for TZDs that may
have beneﬁcial pharmacology.
TZDs Target the Mitochondrial Pyruvate
Carrier and Inhibit Pyruvate Metabolism
Over the years, a number of studies have suggested that,
at higher concentrations, TZDs can exert effects that are
independent of PPARg and transcriptional regulation. Many
of the immediate, nongenomic effects of TZDs are on mito-
chondrial function, including decreased mitochondrial
membrane potential, increased permeability, increased
reactive oxygen species (ROS) abundance, and increased
intracellular calcium.50–52 TZD infusion into isolated rat
liver increased lactate production and decreased glucose
output within 10 minutes,53 and similar effects on lactate
production in astrocytes were independent of gene tran-
scription or protein translation.54 These effects initially
were proposed to be owing to inhibition of mitochondrial
complex I activity.55,56 However, the respiration defects
subsequently were reported to be speciﬁc to pyruvate-
stimulated, and not glutamate-stimulated, respiration, indi-
cating the TZD effect to be upstream of complex I.54,57 In an
attempt to identify a mitochondrial TZD target, a
pioglitazone-based 125I-labeled probe was created and
shown to bind mitochondrial lysates at an approximately
14- to 17-kilodalton protein. Although initial proteomic
studies identiﬁed an outer mitochondrial membrane protein
called mitoNEET,58 mitoNEET knockdown by small inter-
fering RNA did not affect pioglitazone’s ability to increase
lactate production57 and the band cross-linked by the probe
at approximately 14 kilodaltons still was present in liver
lysates from mitoNEET null mice.59
Additional proteomic studies later identiﬁed multiple
peptides for the mitochondrial pyruvate carrier (MPC).59
Pyruvate generated in the cytosol must enter into the
mitochondrial matrix for further metabolism by an inner
mitochondrial membrane solute carrier (Figure 2), which
only recently has been cloned.60,61 In the mitochondrial
matrix, pyruvate can be oxidized by either pyruvate dehy-
drogenase to produce acetyl-CoA, or carboxylated by pyru-
vate carboxylase to form oxaloacetate (Figure 2). Although
the composition and structure of the MPC complex is not
entirely known, 2 proteins, MPC1 and MPC2, are integral
components because deletion of 1 of these subunits causes
loss of the other subunit and loss of pyruvate transport
activity.60–63 Consistent with an inhibitory interaction,
TZD compounds were shown to reduce pyruvate-
stimulated respiration in myocytes, and small interfering
RNA–mediated knockdown of the MPC subunits sensitized
cells/mitochondria to this inhibitory effect of TZDs.64 The
PPARg-sparing TZD, MSDC-0602, inhibited mitochondrial
respiration on pyruvate/malate in a matter of minutes,
and this effect was lost in MPC2 knockout liver mito-
chondria.62 Importantly, because the afﬁnity of MSDC-
0160 and MSDC-0602 for mitochondrial binding is
nearly identical to the traditional TZDs rosiglitazone and
pioglitazone,46,59 it is likely that the MSDC compounds
have a preferential pharmacology toward the mitochon-
drial target. However, MSDC compounds retain the TZD
backbone structure and show minor PPARg binding and
activation. Thus, it is impossible to eliminate the possi-
bility of PPARg-agonism from their pharmacology.30
MPC as a Target for Treating NASH
Several recent studies conducted in rodent models have
evaluated the effects of modulating mitochondrial pyruvate
metabolism on NAFLD and NASH end points. Complete dele-
tion of MPC proteins is lethal at early embryonic stages,65,66
but mice with liver-speciﬁc MPC163 or MPC262 deletion are
viable and outwardly normal. Because mitochondrial pyru-
vate metabolism is essential for the process of gluconeogen-
esis from pyruvate (Figure 2), both mouse models showed a
decreased capacity to convert pyruvate into new glucose.62,63
The liver knockout mice were protected from hyperglycemia
in high-fat diet–induced or genetic (crossed with db/db)
models of insulin resistance and diabetes,62,63 likely owing to
diminished hepatic glucose production. However, the MPC-
deﬁcient livers were not protected from developing hepatic
steatosis in the obese mouse models.62,63
Most mouse genetic or high-fat diet mouse models do
not develop severe liver inﬂammation or ﬁbrosis. To study
the importance of mitochondrial pyruvate metabolism in
NASH, we used a diet enriched in trans-fat, fructose, and
cholesterol (HTF-C), which previously has been shown to
induce NASH-like steatosis, inﬂammation, and ﬁbrosis in
mice.67 Liver-speciﬁc MPC2 deletion and/or treatment with
the PPARg-sparing TZD MSDC-0602 did not signiﬁcantly
improve hepatic steatosis in this HTF-C diet model.48
However, accumulation of oxidized lipids in these livers
was reduced with MSDC-0602 treatment.48 Histologic
scoring and gene expression analyses of these livers showed
a reduction in NAS and ﬁbrosis scoring along with reduced
expression of markers of HSC activation with either genetic
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or pharmacologic MPC inhibition.48 In addition, MSDC-0602
could directly limit HSC activation in vitro.48
As indicated earlier, mice with liver-speciﬁc MPC2
knockout were protected from stellate cell activation on the
HTF-C diet.48 However, both quiescent and activated HSCs
from mice with liver-speciﬁc MPC2 deletion were shown to
normally express Mpc2, indicating that the albumin Cre
transgene inducedMpc2 deletion speciﬁcally in hepatocytes.48
This led us to believe that hepatocytes could release signals
that are received by HSCs to alter their activation. Although
the molecular signals have not yet been identiﬁed, primary
mouse HSCs treated with extracellular vesicles isolated from
the plasma of wild-type or MPC2-deﬁcient mice fed the NASH-
inducing HTF-C diet showed that extracellular vesicles from
the liver-speciﬁcMPC2 null mice elicited less HSC activation.48
Elucidating the mediator(s) contained in these vesicles that
modulate HSC ﬁbrogenesis is an area of ongoing research.
Hepatic inﬂammation is believed to promote the develop-
ment of ﬁbrosis in NASH. Although MPC2 deletion or MSDC-
0602 treatment did not signiﬁcantly improve inﬂammation
histologically or at the gene expression level,48 another study
found thatMPC1 deletion decreased hepatic inﬂammation and
ﬁbrosis after a long-term (44 weeks) 60% high-fat diet.68
Moreover, it was shown that MPC inhibition with a speciﬁc
inhibitor (UK-5099) in isolated hepatocytes acutely decreased
inﬂammatory cytokine expression induced by palmitate and
lipopolysaccharide.68 Collectively, these data suggest thatMPC
inhibition decreases NASH pathology by preventing lipid-
induced hepatocellular damage, decreasing inﬂammation,
maintaining HSC in a quiescent state, and by modulating
mediators released byhepatocytes that control HSC activation.
How Does Modulating Mitochondrial
Pyruvate Metabolism Treat NAFLD?
One of the most signiﬁcant outstanding questions is how
targeting mitochondrial pyruvate metabolism is beneﬁcial in
treating NAFLD. There are several possibilities, as summa-
rized in Figure 3. Evidence is now accumulating that mito-
chondria from NAFLD livers of animal models and human
beings show increased tricarboxylic acid (TCA) cycle
function,69–76 but impaired respiratory coupling.70,77,78
Anaplerotic/cataplerotic ﬂux (nonoxidative) of metabolites
into/out of the TCA cycle also is increased in NAFLD.71 This
increase in mitochondrial metabolic ﬂux in conjunction with
decreased oxidative capacity can lead to increased ROS
formation and hepatocellular damage.71,73,79 It also has
been postulated that lobular hypoxia secondary to high
rates of oxidative metabolism exacerbates ROS formation.77
Increased fatty acid delivery to the liver from insulin-
resistant adipose tissue seems to drive this increase in
TCA cycle and anaplerosis.71 However, in rodent models
some mitochondrial abnormalities can be observed before
profound insulin resistance and hepatic steatosis develops.78
Figure 2. The mitochondrial pyruvate carrier controls hepatic intermediary metabolism. Pyruvate that is generated in the
cytosol via glycolysis or from lactate must enter the mitochondrion for further metabolism. The MPC transports pyruvate
across the inner mitochondrial membrane into the matrix. Pyruvate then can be converted to acetyl-CoA by pyruvate dehy-
drogenase to fuel the TCA cycle. Alternatively, a large proportion of pyruvate in hepatic mitochondria is converted to
oxaloacetate by pyruvate carboxylase, which can be transported to the cytosol and converted to new glucose via the process
of gluconeogenesis. The TCA cycle intermediate citrate can be exported to the cytosol, and becomes the building block for
new fatty acids in de novo lipogenesis. These fatty acids ultimately are converted to triglycerides and either stored in lipid
droplets or excreted in lipoproteins. Inhibition of the MPC can reduce carbon ﬂow into the TCA cycle and alter the ability for
hepatic mitochondria to perform gluconeogenesis and de novo lipogenesis. In addition, reduction of pyruvate oxidation would
enhance fatty acid oxidation, potentially also decreasing hepatic lipid storage. DAG, diacylglycerol; FAO, fatty acid oxidation;
MPCi, mitochondrial pyruvate carrier inhibitor; OAA, oxaloacetate.
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Presently, it still is debated whether this increase in TCA
cycle ﬂux exists after the transition from steatosis to NASH in
human beings. Liver mitochondrial content and oxygen con-
sumption was measured in obese human subjects with and
without NAFLD and subjects with NASH.80 Interestingly,
both subjects with NAFLD and NASH show increased mito-
chondrial content, but although NAFLD subjects had
increased oxygen consumption rates, liver mitochondria from
subjects with NASH showed reduced oxygen consumption,
increased ROS production, and oxidative damage.80 Although
this human study did not assess TCA cycle ﬂux or
anaplerosis/cataplerosis rates, it appears that mice fed a
trans-fat diet inducing NASH still show increased TCA cycle
activity.73 In addition, pigs fed a NASH-inducing Western diet
showed increased citrate synthase activity, which can serve
as a proxy for both mitochondrial content and TCA cycle
activity.81 With this model of mitochondrial metabolic
overload in NAFLD, improvements could be envisioned by
either increasing oxidative capacity, as seen with exercise
training,79,82–84 or by decreasing the metabolite transport
into mitochondria, which is driving the increase in TCA
ﬂux.68,71
Figure 3. The multifaceted beneﬁts of MPC inhibition in NASH. Systemic MPC inhibition and the associated increased
insulin sensitivity could improve nearly every aspect of the pathophysiology of NASH. Improved insulin sensitivity would
decrease adipose tissue lipolysis of free fatty acids, and reduce the lipid load on the liver. Reduced hyperinsulinemia and
increased hepatic insulin sensitivity would decrease de novo lipogenesis and decrease gluconeogenesis. Blocking pyruvate
entry into the mitochondrion also decreases TCA cycle ﬂux, which is increased in NAFLD. This normalization of TCA cycle ﬂux
to oxidative capacity would result in decreased reactive oxygen species and cell damage signals. This would reduce
inﬂammation. MPC inhibition on inﬂammatory cells such as Kupffer cells likely also directly reduces inﬂammation. Reduced
inﬂammation, as well as direct effects, then would reduce the activation and ﬁbrogenesis of hepatic stellate cells. Finally, it also
has been observed that MPC inhibition can induce a hepatocyte-derived signal contained within extracellular vesicles that can
reduce stellate cell activation. TGF-b, transforming growth factor b.
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Inhibiting pyruvate ﬂux into the mitochondrion also
would limit metabolic substrates, driving the enhanced TCA
cycle ﬂux and anaplerosis in NAFLD/NASH. In many organs,
pyruvate is a major metabolite fueling the TCA cycle after
pyruvate dehydrogenase converts pyruvate to acetyl-CoA
(Figure 2), although in the liver a majority of pyruvate is
carboxylated via the pyruvate carboxylase enzyme into
oxaloacetate (OAA) under many nutritional conditions
(Figure 2). Hepatocytes with MPC1 or MPC2 deletion62,63,68
or treated with MSDC-060262 show decreased ﬂux of
pyruvate carbons into TCA cycle intermediates. However,
more sophisticated isotopomer ﬂux experiments and
modeling are required to fully assess the MPCs role in
governing TCA cycle and anaplerotic activity. Knockout of
MPC proteins likely is well compensated for by increased
rates of fatty acid oxidation and amino acid utilization.62,63
Interestingly, increased glutaminolysis recently was shown
to drive HSC activation,85 allowing speculation that MPC
inhibition and enhanced glutamine metabolism in hepato-
cytes could limit the availability of glutamine for HSCs and
therefore decrease HSC activation.
As noted earlier, intrahepatic triglyceride levels are
affected by several metabolic processes, including fatty acid
oxidation, de novo lipogenesis, and release of fatty acids from
adipose tissues, which are dysregulated in obesity and insulin
resistance. Altering mitochondrial pyruvate metabolism could
affect each one of these pathways. For example, blocking the
ability to oxidize pyruvate from glucose leads to increased
oxidation of fatty acids in MPC-deﬁcient hepatocytes62 or he-
patocytes treated with MSDC-0602.46 Mitochondrial pyruvate
metabolism into citrate is also the initial step in de novo lipo-
genesis (Figure2), and thus inhibitingMPCactivitymay reduce
hepatic lipid synthesis. However, reduced MPC expression or
MPC inhibition with UK-5099 did not greatly alter lipid syn-
thesis owing to compensation by increased amounts of gluta-
mine carbons into newly synthesized lipids.86,87 In NAFLD
driven by insulin resistance, a large proportion of fatty acids
delivered to the liver are released fromadipose tissue lipolysis.
Because the obese liver-speciﬁc MPC-deﬁcient mice still
are peripherally insulin-resistant, it is likely that enhanced
adipose tissue lipolysis drives the triglyceride accumulation
in these livers. On the other hand, improving insulin sensi-
tivity would reduce hyperinsulinemia, which then should
reduce hepatic de novo lipogenesis. Indeed, treatment with
pioglitazone or MSDC-0602 signiﬁcantly reversed hepatic
triglyceride accumulation in high-fat diet–fed mice,88
potentially by both reducing hepatic de novo lipogenesis
and peripheral effects. Taken together, these results suggest
that MPC deﬁciency or inhibition could alter the numerous
metabolic pathways regulating hepatic steatosis, but meta-
bolic compensation likely modiﬁes these effects. In our
opinion, this further points to the importance of correcting
peripheral insulin resistance in the treatment of NASH.
Conclusions
NAFLD and NASH are an increasingly prevalent and
costly health burden with no approved therapeutics at this
time. The MPC is an attractive target in NASH because of the
many metabolic alterations that could occur in both hepa-
tocytes and stellate cells with inhibition of mitochondrial
pyruvate metabolism. Intriguingly, this MPC-driven phar-
macology could have been an unrecognized beneﬁt of
treating NASH with pioglitazone. Indeed, pioglitazone
treatment decreases TCA cycle ﬂux and anaplerosis in
rodent models of NASH.74 In addition to the liver-centric
effects of MPC inhibition, improving peripheral insulin
sensitivity with both the traditional and PPARg-sparing
TZDs would both target an underlying driver of NAFLD and
reduce fatty acid delivery to the liver (Figure 3).
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